TY - JOUR
T1 - Evaluation of late adverse events in long-term Wilms' tumor survivors
AU - Van Dijk, Irma W.E.M.
AU - Oldenburger, Foppe
AU - Cardous-Ubbink, Mathilde C.
AU - Geenen, Maud M.
AU - Heinen, Richard C.
AU - De Kraker, Jan
AU - Van Leeuwen, Flora E.
AU - Van Der Pal, Helena J.H.
AU - Caron, Huib N.
AU - Koning, Caro C.E.
AU - Kremer, Leontien C.M.
PY - 2010/10/1
Y1 - 2010/10/1
N2 - Purpose: To evaluate the prevalence and severity of adverse events (AEs) and treatment-related risk factors in long-term Wilms' tumor (WT) survivors, with special attention to radiotherapy. Methods and Materials: The single-center study cohort consisted of 185 WT survivors treated between 1966 and 1996, who survived at least 5 years after diagnosis. All survivors were invited to a late-effects clinic for medical assessment of AEs. AEs were graded for severity in a standardized manner. Detailed radiotherapy data enabled us to calculate the equivalent dose in 2 Gy fractions (EQD2) to compare radiation doses in a uniform way. Risk factors were evaluated with multivariate logistic regression analysis. Results: Medical follow-up was complete for 98% of survivors (median follow-up, 18.9 years; median attained age, 22.9 years); 123 survivors had 462 AEs, of which 392 had Grade 1 or 2 events. Radiotherapy to flank/abdomen increased the risk of any AE (OR, 1.08 Gy-1 [CI, 1.04-1.13]). Furthermore, radiotherapy to flank/abdomen was associated with orthopedic events (OR, 1.09 Gy-1 [CI, 1.05-1.13]) and second tumors (OR, 1.11 Gy-1 [CI, 1.03-1.19]). Chest irradiation increased the risk of pulmonary events (OR, 1.14 Gy-1 [CI, 1.06-1.21]). Both flank/abdominal and chest irradiation were associated with cardiovascular events (OR, 1.05 Gy-1 [CI, 1.00-1.10], OR, 1.06 Gy-1 [CI, 1.01-1.12]) and tissue hypoplasia (OR, 1.17 Gy-1 [CI, 1.10-1.24], OR 1.10 Gy-1 [CI, 1.03-1.18]). Conclusion: The majority of AEs, overall as well as in irradiated survivors, were mild to moderate. Nevertheless, the large amount of AEs emphasizes the importance of follow-up programs for WT survivors.
AB - Purpose: To evaluate the prevalence and severity of adverse events (AEs) and treatment-related risk factors in long-term Wilms' tumor (WT) survivors, with special attention to radiotherapy. Methods and Materials: The single-center study cohort consisted of 185 WT survivors treated between 1966 and 1996, who survived at least 5 years after diagnosis. All survivors were invited to a late-effects clinic for medical assessment of AEs. AEs were graded for severity in a standardized manner. Detailed radiotherapy data enabled us to calculate the equivalent dose in 2 Gy fractions (EQD2) to compare radiation doses in a uniform way. Risk factors were evaluated with multivariate logistic regression analysis. Results: Medical follow-up was complete for 98% of survivors (median follow-up, 18.9 years; median attained age, 22.9 years); 123 survivors had 462 AEs, of which 392 had Grade 1 or 2 events. Radiotherapy to flank/abdomen increased the risk of any AE (OR, 1.08 Gy-1 [CI, 1.04-1.13]). Furthermore, radiotherapy to flank/abdomen was associated with orthopedic events (OR, 1.09 Gy-1 [CI, 1.05-1.13]) and second tumors (OR, 1.11 Gy-1 [CI, 1.03-1.19]). Chest irradiation increased the risk of pulmonary events (OR, 1.14 Gy-1 [CI, 1.06-1.21]). Both flank/abdominal and chest irradiation were associated with cardiovascular events (OR, 1.05 Gy-1 [CI, 1.00-1.10], OR, 1.06 Gy-1 [CI, 1.01-1.12]) and tissue hypoplasia (OR, 1.17 Gy-1 [CI, 1.10-1.24], OR 1.10 Gy-1 [CI, 1.03-1.18]). Conclusion: The majority of AEs, overall as well as in irradiated survivors, were mild to moderate. Nevertheless, the large amount of AEs emphasizes the importance of follow-up programs for WT survivors.
KW - Adverse effects
KW - Late effects
KW - Nephroblastoma
KW - Radiotherapy
KW - Wilms' tumor
UR - http://www.scopus.com/inward/record.url?scp=84755161100&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2009.08.016
DO - 10.1016/j.ijrobp.2009.08.016
M3 - Article
C2 - 20137867
AN - SCOPUS:84755161100
SN - 0360-3016
VL - 78
SP - 370
EP - 378
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 2
ER -